- Melatonin has no measurable effect on sleep duration, latency, or onset — we analyzed 200,000+ sleep records from hundreds of users and found that the thing most people take it for, better sleep, doesn't show up in the data.
- It does lower overnight heart rate and raise HRV, peaking around days 3–5 — the effect is statistically significant but fades after roughly a week, suggesting melatonin acts as a circadian timing cue rather than a sedative.
- There is no withdrawal or rebound effect — when users stop taking melatonin, metrics return to baseline within two days rather than worsening, with a brief carry-over benefit immediately after stopping.
All articlesSupplement Tracking
Melatonin’s Real Effect Peaks on Day 4 - And It's NOT Sleep
By Rocio Mexia Diaz, Alistair Brownlee and Halvard Ramstad
March 5, 2026
Get the latest Terra Research reports
By continuing, I agree to the Privacy Policy and Terms of Service.
What is Melatonin? How Does it Work?
Melatonin is a hormone our bodies naturally produce at night, and it acts as a “darkness signal” that helps coordinate circadian timing and nighttime physiology. It targets our brain’s circadian pacemaker (our biological clock) to shift circadian phase. [1]
We analyzed 200,000+ sleep records from hundreds of users who reported taking melatonin at least once. To isolate the effects of melatonin, we excluded the nights where users consumed alcohol, late caffeine or showed illness symptoms (specifically tagged illness). Using linear mixed effect models, we compared nights where users took melatonin vs those where they did not to understand how melatonin influences our physiology and sleep at night.
This is real‑world, self‑reported data with strong within‑person controls, but it is still observational. This blog answers “what changes when we take melatonin compared to when we don’t” but is not equivalent to a clinical trial study. For a comparative analysis across users, we computed the rolling Z-scores for all metrics to let us compare people on different absolute scales (e.g., naturally high or low HRV), but it also means the results are about relative change rather than absolute values.
Just a quick, friendly note: we’re not doctors, and nothing in this post should be taken as medical advice or a recommendation to start (or stop) taking melatonin supplements. We’re simply sharing what the numbers show among people who already track it. And as with anything self-reported, those melatonin tags are only as good as the info people enter, so please keep that in mind.
The Effects of Melatonin Over Time
We examined physiological trajectories (breathing rate, average night time heart rate and HRV) over consecutive nights of melatonin use. Each day within a melatonin “burst” was compared against the user’s non‑melatonin baseline using a mixed‑effects model. We focused on bursts up to 30 days to maintain sample size and stability.
Day 1 shows minimal separation from baseline, our body’s physiology looks “the same”. HRV increases and HR decreases over the first few days, with the largest separation around days 3–5. These effects meet our statistical threshold (p < 0.05) and a small‑to‑moderate effect size (|Cohen’s d| > 0.2). After roughly a week, variability across users increases and the average effect attenuates toward baseline.
Breathing rate did not show consistent or statistically significant deviations from baseline.
The data shows that the benefit is not immediate for most users; it builds over a few days. After around day 5, the average effect fades and we mostly observe between‑person variation. This suggests melatonin does not have a uniform long‑term effect: some users continue to show improvements while others return to baseline. This pattern aligns with melatonin acting as a timing cue rather than a steadily accumulating sedative effect.
Withdrawal Effects
We analyzed the two weeks after a period of consecutive melatonin use and compared those nights to each user’s non‑melatonin baseline using the same mixed‑effects framework.
We observed a brief “carry‑over” pattern: HRV is higher and HR is lower immediately after stopping, but these differences fade rapidly. Within the next 2 days metrics return to baseline level on average.
What does this mean? If melatonin use is stopped, the body doesn’t appear to experience a withdrawal or rebound effect, and in fact residual benefits are present immediately after stopping.
Physiological Effects on Sleep Performance
Melatonin has no visible effect on our sleep duration, latency and onset. Counterintuitive?
A possible explanation for this unusual insight is that users might take melatonin on nights they expect to be harder (travel, stress, early wake…) so even if melatonin helps in falling asleep, these tags are reflecting the context rather than the melatonin effects. In fact, clinical studies have also shown modest effects on sleep, which aligns with environmental factors dominating our signal. [2]
Key Takeaways
Melatonin works best as a timing cue for your body clock, not a sedative that keeps stacking stronger effects night after night [3]. It helps your system recognize “biological night” and can shift circadian timing when taken consistently.
In our data, the clearest benefits weren’t on night one: physiology looked most “recovered” on days 3–5 (lower overnight HR, higher HRV). After roughly a week of continuous use, those HR/HRV differences fade back toward baseline, suggesting melatonin may add less once your rhythm and routine have stabilized. When users stopped, we didn’t see a withdrawal pattern, metrics returned to baseline quickly, consistent with clinical findings that discontinuation of prolonged‑release melatonin is not associated with rebound insomnia or withdrawal symptoms [4].
Finally, melatonin has a greater impact on our physiology than it has on our sleep. Melatonin is often taken on “hard nights,” and clinical evidence suggests its average sleep effects are modest, so real‑world context can dominate these “poor sleep” durations.
References
[1] Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. Annu Rev Pharmacol Toxicol. 2016;56:361-83. doi: 10.1146/annurev-pharmtox-010814-124742. Epub 2015 Oct 23. PMID: 26514204; PMCID: PMC5091650.
[2] Asim Alawad, Wala Sati, Sara M I Ahmed, Moayed Elgassim, Mohamad Elgassim, Abderahman Balal, Melatonin-induced symptomatic bradycardia in an otherwise healthy male: a case report, Oxford Medical Case Reports, Volume 2024, Issue 8, August 2024, omae096, https://doi.org/10.1093/omcr/omae096
[3] Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. Annu Rev Pharmacol Toxicol. 2016;56:361-83. doi: 10.1146/annurev-pharmtox-010814-124742. Epub 2015 Oct 23. PMID: 26514204; PMCID: PMC5091650.
[4] Lemoine P, Garfinkel D, Laudon M, Nir T, Zisapel N. Prolonged-release melatonin for insomnia - an open-label long-term study of efficacy, safety, and withdrawal. Ther Clin Risk Manag. 2011;7:301-11. doi: 10.2147/TCRM.S23036. Epub 2011 Jul 26. PMID: 21845053; PMCID: PMC3150476.
